Small Cell Lung Cancer Therapeutics Market Global Outlook and Overview 2018-2026 - CMFE News

Cancer is rapidly becoming a global concern. According to 2015 report by the American Cancer Society, 1 in 8 deaths globally is due to cancer. Research findings suggest that lung cancer is the second most commonly diagnosed cancer. It also has one of the highest mortality rates both in men and women. Lung cancer is the abnormal growth of cells in lungs. As more malignant cells develop, these start to spread to other parts of the body. Non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) are the two primary types of lung cancer. Research findings suggest that small cell lung cancer accounts for approximately 10% to 20% of all lung cancers. Small cell lung cancer is also called oat cell lung cancer. It is linked to junk food, physical inactivity, HIV infection, tobacco, chronic infections, and other hereditary family history. Decrease in active and passive smoking significantly reduces the incidence of small cell lung cancer. The common symptoms of lung cancer are blood in sputum, cough, debility, and dyspnea. Overall, small cell lung cancer has poor prognosis in comparison with non-small cell lung cancer. Research findings also suggest that small cell lung cancer is detected during the final stages of disease progression, and hence it has high mortality rate. Presently, there is no treatment that completely cures small cell lung cancer.

Report Overview @ https://www.transparencymarketresearch.com/small-cell-lung-cancer-therapeutics-market.html

The global small cell lung cancer therapeutics market is projected to grow at a rapid pace in the next few years. Growth of the global small cell lung cancer therapeutics market is attributed to rise in number of people suffering from small cell lung cancer and increase in adoption of unhealthy lifestyle specifically in developing and developed countries which leads to change in eating and sleeping habits. Increase in demand for personalized medicines, platinum based chemotherapies, targeted therapies, and better diagnostic facilities are likely to propel the global small cell lung cancer (SCLC) therapeutics market. Additionally, increase in government initiatives and rise in health awareness are the factors expected to augment the global market. However, rise in cost of treatment and side effects of cancer therapies & drugs are likely to hamper the growth of the global SCLC therapeutics market.

The global small cell lung cancer therapeutics market is divided into type of drug therapy and distribution channel. In terms of type of drug therapy, the global small cell lung cancer therapeutics market can be categorized into platinum drug therapy, targeted therapy drugs, and immunotherapy drugs. The platinum drug therapy segment is projected to account for large share of the small cell lung cancer therapeutics market due to effectiveness of the therapy. By distribution channel, the global small cell lung cancer therapeutics market is divided into, retail pharmacies hospital pharmacies and online pharmacies.

Request Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=49311

Geographically, the global small cell lung cancer therapeutics market can be segmented into North America, Asia Pacific, Europe, Latin America, and Middle East & Africa. North America is projected to lead the global small cell lung cancer therapeutics market during the forecast period. This is attributed to advanced health care setup supported by reimbursement policies, increase in awareness among people about early diagnosis, adoption of new techniques, and presence of key players. Europe and Asia Pacific are expected to be lucrative markets from 2018 to 2026. The small cell lung cancer therapeutics market in these regions is driven by increase in the geriatric population, rise in government funding, and presence of rapidly developing economies such as China, India, and Singapore.

Some of the key players operating in the global small cell lung cancer therapeutics market are ZIOPHARM Oncology, GlaxoSmithKline, Menarini, Bristol-Myers Squibb, and Sanofi etc.

http://bit.ly/2EUmkY8